Preoperative care/Catalogs/Beta-blocker evidence table

Randomized controlled trials of perioperative beta-blockers* with at least 100 total patients.
(See legend and notes at bottom on the table)

	Patients	Intervention	Comparison	Outcome	Results
					Mortality		Stroke		Beta-blocker toxicity
					Rx	Control	Rx	Control	Rx	Control
Decrease IV 2009 Drug provided by Merck KGaA	1066 patients: •estimated risk of perioperative cardiovascular death of ≥ 1% • 0% vascular surgery • RCRI = 2: ~100%	Bisoprolol • Started a median of 34 days preop • Minimum allowed HR↑: >50 bpm	Open label	Mortality at 30 days	1.9%	3.0%	0.8%	0.6%	Heart failure, clinically significant bradycardia or hypotension:
									0.6%	0.4%
POISE 2008 Partially funded by AstraZeneca	8351 patients: • 42% vascular surgery • RCRI = 2: uncertain	Metoprolol succinate • Started day of surgery • Minimum allowed HR↑: > 50 bpm	Placebo	Mortality at two weeks	Overall		1%	0.5%	Clinically significant hypotension:
					3.1%	2.3%			15%	9.7%
					Vascular pts
					Significant benefit on composite events. Mortality by surgery type not reported.
BBSA 2007 Partially funded by industry.	224 patients: • 1% vascular surgery • RCRI = 2: uncertain	Bisoprolol • Started day of surgery Minimum allowed HR↑: > 50bpm	Placebo	Mortality at one year	0.9	0.9	1.8%	0%	Hypotension:
									0%	2.7%
DIPOM 2006 Partially funded by AstraZeneca	921 patients: • 7% vascular surgery • RCRI > 2: uncertain • All had diabetes	Metoprolol succinate • Started 0-1 days preop • Minimum allowed HR↑: >55 bpm	Placebo	Mortality at a median of 18 months	16%	16%	0.4%	0%	Hypotension reported as an ADR:
									0.4%	0.2%
MaVS 2006 No industry funding.	496 patients: • 100% vascular surgery • RCRI = 2: 40%	Metoprolol • Start: day of surgery • Minimum allowed HR↑: > 50 bpm while awake; >45 bpm while asleep.	Placebo	Hospital mortality	0%	1.6%	2.0%	1.6%	Intraoperative hypotension treated:
									46%	34%
POBBLE 2005 No industry funding.	103 patients: • 100% vascular surgery • RCRI > 2: uncertain	Metoprolol • Start with test dose one day preop • Minimum allowed HR↑: > 50 bpm	Placebo (anesthesiologists were not blinded)	Mortality at 30 days	3%	1%	2%	0%	Intraoperative inotropes given:
									92%	64%
Decrease I 1999 Uncertain funding.	112 patients: • 100% vascular surgery • RCRI = 2: uncertain, at least 67% • Abnl stress echo: 100%	Bisoprolol • Started a median of 37 days preop • Minimum allowed HR↑: > 50 bpm	Open label	Mortality at 30 days	3.4% (8.5%‡)	17.0%	Not reported		Discontinuation of study drug due to ADRs:
									0%	0%
Mangano/ MSPI 1996 No industry funding.	200 patients: • 41% vascular surgery • RCRI > 2: uncertain	Atenolol • Minimum allowed HR↑: > 55 bpm	Placebo	Hospital mortality	4%	2%	4%	1%	Intraoperative inotropes given:
									13%	13%
* This table does not include trials that used beta-blockers only for premedication or only during postoperative care. † Minimum allowed HR. The lowest heart rate allowed before beta-blockers were withheld. ‡ The DECREASE I trial was stopped early when a significant benefit was observed and the relative risk was 0.2. By Bayesian analysis, the relative risk is more likely to be 0.5 which leads to an event rate in the treatment group of 8.5%. Notes: Color indicates statistically significant differences with green indicating benefit and red indicating harm. BBSA noted more drug toxicity among patients with abnormal beta1-adrenergic receptor genetic polymorphisms. Mavs had trend toward most benefit in RCRI = 3.